Decoy Therapeutics (DCOY) Income from Continuing Operations (2015 - 2026)
Decoy Therapeutics (DCOY) posted quarterly Income from Continuing Operations of 2292215.0 for Q1 2026, down 33.05% year-over-year from 3423902.78 in Q1 2025, and up 74.63% quarter-over-quarter from 9034562.0 in Q4 2025.
Decoy Therapeutics (DCOY) Income from Continuing Operations (2015 - 2026) Analysis & Trends
Decoy Therapeutics (DCOY) has reported Income from Continuing Operations for 12 consecutive years, with 2292215.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Income from Continuing Operations fell 33.05% year-over-year to 2292215.0; the TTM figure through Mar 2026 stood at 13189178.0 (down 131.71% YoY), while the FY2025 annual figure was 34400305.0, down 50.66% from the prior year.
- Income from Continuing Operations climbed to 2292215.0 in Q1 2026 per DCOY's latest filing, from 9034562.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 895130.0 in Q3 2025 and bottomed at 19520636.0 in Q4 2022.
- Historically, Income from Continuing Operations has averaged 4614336.53 across 5 years, with a median of 2292215.0 in 2026.
- Annual changes were most pronounced in 2023 — Income from Continuing Operations surged 94.99% — and 2025, when it plunged 507.45%.
- Decoy Therapeutics' Income from Continuing Operations stood at 19520636.0 in 2022, then soared by 94.99% to 978656.0 in 2023, then tumbled by 51.97% to 1487292.0 in 2024, then slumped by 507.45% to 9034562.0 in 2025, then soared by 74.63% to 2292215.0 in 2026.
- Business Quant data shows DCOY's Income from Continuing Operations at 2292215.0 in Q1 2026, 9034562.0 in Q4 2025, and 895130.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -174.37 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Decoy Therapeutics | 1.75 Mn | 1.75 Mn | - | -2.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -2.62 Mn |
| Mar 31, 2026 | -2.29 Mn |
| Dec 31, 2025 | -9.03 Mn |
| Sep 30, 2025 | -895,130.00 |
| Jun 30, 2025 | -967,271.00 |
| Mar 31, 2025 | -1.72 Mn |
| Dec 31, 2024 | -1.49 Mn |
| Sep 30, 2024 | -1.01 Mn |
| Jun 30, 2024 | -1.47 Mn |
| Mar 31, 2024 | -1.78 Mn |
| Dec 31, 2023 | -978,656.00 |
| Sep 30, 2023 | -2.53 Mn |
| Jun 30, 2023 | -3.97 Mn |
| Mar 31, 2023 | -5.42 Mn |
| Dec 31, 2022 | -19.52 Mn |
| Sep 30, 2022 | -14.49 Mn |
| Jun 30, 2022 | -4.76 Mn |
| Mar 31, 2022 | -6.12 Mn |
| Dec 31, 2021 | -4.14 Mn |
| Sep 30, 2021 | -4.02 Mn |